Synthesis and quantitative structure-activity relationship of imidazotetrazine prodrugs with activity independent of O6-methylguanine-DNA- methyltransferase, DNA mismatch repair, and p53

Journal of Medicinal Chemistry

Volumn 56, Issue 17, 2013, Pages 7120-7132

  Pletsas, Dimitrios ^a   Garelnabi, Elrashied A E ^a,b   Li, Li ^a   Phillips, Roger M ^a   Wheelhouse, Richard T ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b UNIVERSITY OF KHARTOUM   (Sudan)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [(4 METHOXY 2 NITROPHENYL)(METHYL)AMINO]ETHYL] 4OXO 3,4 DIHYDROIMIDAZO[5,1 D][1,2,3,5]TETRAZINE 8 CARBOXAMIDE; 3 [2 [METHYL(4 METHYL 3 NITROPHENYL)AMINO]ETHYL] 4 OXO 3,4 DIHYDROIMIDAZO[5,1 D][1,2,3,5]TETRAZINE 8 CARBOXAMIDE; 6 O METHYLGUANINE; ANTINEOPLASTIC AGENT; CISPLATIN; DNA METHYLTRANSFERASE; GUANINE; IMIDAZOTETRAZINE; ION; METHYLTRANSFERASE; PROTEIN P53; TEMOZOLOMIDE; TERT BUTYL 2 [8 CARBAMOYL 4 OXOIMIDAZO(5,1 D)(1,2,3,5) TETRAZIN 3(4H) YL]ETHYL(4 CHLOROPHENYL) CARBAMATE; UNCLASSIFIED DRUG;

ARTICLE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; MISMATCH REPAIR; MUSTARD; QUANTITATIVE ANALYSIS; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; TUMOR CELL; WILD TYPE;

BASE PAIR MISMATCH; DNA REPAIR; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PRODRUGS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84884239964     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401121k     Document Type: Article

References (39)

1. Sarkaria, J. N.; Kitange, G. J.; James, C. D.; Plummer, R.; Calvert, H.; Weller, M.; Wick, W. Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma Clin. Cancer Res. 2008, 14, 2900-2908
2. Zhang, J.; Stevens, M. F. G.; Bradshaw, T. D. Temozolomide: Mechanisms of Action, Repair and Resistance Curr. Mol. Pharmacol. 2012, 5, 102-114
3. Darkes, M. J. M.; Plosker, G. L.; Jarvis, B. Temozolomide a Review of its Use in the Treatment of Malignant Gliomas, Malignant Melanoma and Other Advanced Cancers Am. J. Cancer 2002, 1, 55-80
4. Stevens, M. F. G.; Hickman, J. A.; Langdon, S. P.; Chubb, D.; Vickers, L.; Stone, R.; Baig, G.; Goddard, C.; Gibson, N. W.; Slack, J. A.; Newton, C.; Lunt, E.; Fizames, C.; Lavelle, F. Antitumor Imidazotetrazines 13. Antitumor Activity and Pharmacokinetics in Mice of 8-Carbamoyl-3-Methyl-Imidazo-[5,1-d]-1, 2,3,5-tetrazin-4(3H)-one (CCRG 81045-M&B-39831), a Novel Drug with Potential as an Alternative to Dacarbazine Cancer Res. 1987, 47, 5846-5852
5. Shealy, Y. F.; Krauth, C. A. Imidazoles. II. 5(or 4)-(Monosubstituted triazeno)imidazole-4(or 5)-carboxamides J. Med. Chem. 1966, 9, 35-38
6. Denny, B. J.; Wheelhouse, R. T.; Stevens, M. F. G.; Tsang, L. L. H. NMR and Molecular Modeling Investigation of the Mechanism of Activation of the Antitumor Drug Temozolomide and its Interaction with DNA Biochemistry 1994, 33, 9045-9051
7. Wheelhouse, R. T.; Stevens, M. F. G. Decomposition of the Antitumour Drug Temozolomide in Deuteriated Phosphate Buffer: Methyl Group Transfer is Accompanied by Deuterium Exchange J. Chem. Soc., Chem. Commun. 1993, 1177-1179
8. McGarrity, J. F.; Smyth, T. Hydrolysis of Diazomethane-Kinetics and Mechanism J. Am. Chem. Soc. 1980, 102, 7303-7308
9. Svilar, D.; Dyavaiah, M.; Brown, A. R.; Tang, J.-b.; Li, J.; McDonald, P. R.; Shun, T. Y.; Braganza, A.; Wang, X.-h.; Maniar, S.; St Croix, C. M.; Lazo, J. S.; Pollack, I. F.; Begley, T. J.; Sobol, R. W. Alkylation Sensitivity Screens Reveal a Conserved Cross-species Functionome Mol. Cancer Res. 2012, 10, 1580-1596
10. Schmidt, B. F.; Snyder, E. J.; Carroll, R. M.; Farnsworth, D. W.; Michejda, C. J.; Smith, R. H. Triazinines: Synthesis and Proteolytic Decomposition of a New Class of Cyclic Triazenes J. Org. Chem. 1997, 62, 8660-8665
11. Schmiedekamp, A.; Smith, R. H.; Michejda, C. J. Ab Initio Studies of Triazenes in Relation to Experimental Findings J. Org. Chem. 1988, 53, 3433-3436
12. Smith, R. H.; Wladkowski, B. D.; Taylor, J. E.; Thompson, E. J.; Pruski, B.; Klose, J. R.; Andrews, A. W.; Michejda, C. J. Acid-Catalyzed Decomposition of 1-Alkyltriazolines-a Mechanistic Study J. Org. Chem. 1993, 58, 2097-2103
13. Wang, Y.; Wheelhouse, R. T.; Zhao, L.; Langnel, D. A. F.; Stevens, M. F. G. Antitumour Imidazotetrazines. Part 36. Conversion of 5-aminoimidazole-4- carboxamide to Imidazo-[5,1-d]-1,2,3,5-tetrazin4(3H)-ones and Imidazo-[1,5-a]-1,3,5-triazin4(3H)-ones Related in Structure to the Antitumour Agents Temozolomide and Mitozolomide J. Chem. Soc., Perkin Trans. 1 1998, 1669-1676
14. Arrowsmith, J.; Jennings, S. A.; Langnel, D. A. F.; Wheelhouse, R. T.; Stevens, M. F. G. Antitumour Imidazotetrazines. Part 39. Synthesis of Bis(imidazotetrazine)s with Saturated Spacer Groups J. Chem. Soc., Perkin Trans. 1 2000, 4432-4438
15. Garelnabi, E. A. E.; Pletsas, D.; Li, L.; Kiakos, K.; Karodia, N.; Hartley, J. A.; Phillips, R. M.; Wheelhouse, R. T. Strategy for Imidazotetrazines with Anticancer Activity Independent of MGMT and MMR ACS Med. Chem. Lett. 2012, 3, 965-968
16. Pletsas, D.; Wheelhouse, R. T.; Pletsa, V.; Nicolaou, A.; Jenkins, T. C.; Bibby, M. C.; Kyrtopoulos, S. A. Polar, Functionalized Guanine- O6 Derivatives Resistant to Repair by O6 -Alkylguanine-DNA Alkyltransferase: Implications for the Design of DNA-modifying Drugs Eur. J. Med. Chem. 2006, 41, 330-339
17. Arris, C. E.; Bleasdale, C.; Calvert, A. H.; Curtin, N. J.; Dalby, C.; Golding, B. T.; Griffin, R. J.; Lunn, J. M.; Major, G. N.; Newell, D. R. Probing the Active-Site and Mechanism of Action of O 6-Methylguanine-DNA Methyltransferase With Substrate-Analogs (O 6-Substituted Guanines) Anti-Cancer Drug Des. 1994, 9, 401-408
18. 15N) Magnetic Resonance Investigation of Temozolomide and Mitozolomide J. Chem. Soc., Perkin Trans. 1 1995, 249-252
19. Barvaux, V. A.; Ranson, M.; Brown, R.; McElhinney, R. S.; McMurry, T. B. H.; Margison, G. P. Dual Repair Modulation Reverses Temozolomide Resistance in Vitro Mol. Cancer Ther. 2004, 3, 123-127
20. McElhinney, R. S.; Donnelly, D. J.; McCormick, J. E.; Kelly, J.; Watson, A. J.; Rafferty, J. A.; Elder, R. H.; Middleton, M. R.; Willington, M. A.; McMurry, T. B.; GP, M. Novel O 6-(Hetarylmethyl)guanines Having Basic Rings in the Side Chain J. Med. Chem. 1998, 41, 5265-5271
21. Judson, P. L.; Blair Harkness, C.; Boente, M. P.; Downs, L. S., Jr; Argenta, P. A.; Carson, L. F. A Phase II Evaluation of Temozolomide in Patients with Recurrent Epithelial Ovarian Cancer Gynecol. Oncol. 2004, 93, 667-670
22. Boyd, M. R.; Pauli, K. D. Some Practical Considerations and Applications of the National-Cancer-Institute in-Vitro Anticancer Drug Discovery Screen Drug Development Res. 1995, 34, 91-109
23. Leteurtre, F.; Kohlhagen, G.; Paull, K. D.; Pommier, Y. Topoisomerase II Inhibition and Cytotoxicity of the Anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute Preclinical Antitumor Drug Discovery J. Nat. Cancer Inst. 1994, 86, 1239-1244
24. Karran, P.; Attard, N. Thiopurines in Current Medical Practice: Molecular Mechanisms and Contributions to Therapy-related Cancer Nat. Rev. Cancer 2008, 8, 24-36
25. Karran, P. Thiopurines, DNA Damage, DNA Repair and Therapy-related Cancer Br. Med. Bull. 2006, 79-80, 153-170
26. Genecards (The Human Genome Compendium) http://www.genecards.org, accessed March 7, 2013.
27. Nishizuka, S.; Charboneau, L.; Young, L.; Major, S.; Reinhold, W. C.; Waltham, M.; Kouros-Mehr, H.; Bussey, K. J.; Lee, J. K.; Espina, V. Proteomic Profiling of the NCl-60 Cancer Cell Lines Using New High-density Reverse-phase Lysate Microarrays Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 14229-14234
28. Hirose, Y.; Katayama, M.; Stokoe, D.; Haas-Kogan, D. A.; Berger, M. S.; Pieper, R. O. The p38 Mitogen-Activated Protein Kinase Pathway Links the DNA Mismatch Repair System to the G2 Checkpoint and to Resistance to Chemotherapeutic DNA-Methylating Agents Mol. Cell. Biol. 2003, 8306-8315
29. Zhang, J.; Stevens, M. F. G.; Hummersone, M.; Madhusudan, S.; Laughton, C. A.; Bradshaw, T. D. Certain Imidazotetrazines Escape O 6-Methylguanine-DNA Methyltransferase and Mismatch Repair Oncology 2011, 80, 195-207
30. Liu, L.; Taverna, P.; Whitacre, C. M.; Chatterjee, S.; Gerson, S. L. Pharmacologic Disruption of Base Excision Repair Sensitizes Mismatch Repair-deficient and -proficient Colon Cancer Cells to Methylating Agents Clin. Cancer Res. 1999, 5, 2908-2917
31. Dinca, E. B.; Lu, K. V.; Sarkaria, J. N.; Pieper, R. O.; Prados, M. D.; Haas-Kogan, D. A.; VandenBerg, S. R.; Berger, M. S.; James, C. D. p53 Small-molecule Inhibitor Enhances Temozolomide Cytotoxic Activity against Intracranial Glioblastoma Xenografts Cancer Res. 2008, 10034-10039
32. Mladek, A. C.; Ramirez, Y.; Pletsas, D.; Wheelhouse, R. T.; Phillips, R. M.; Ross, A. H.; Knudson, K.; Sarkaria, J. N. Cytotoxicity of a Novel Bi-functional Temozolomide Analog, DP68, Is Independent of MGMT Status in Glioblastoma Models Proc. Am. Assoc. Cancer Res. 2013, 4476, abstract
33. Boberg, F. Über 1.2-Dithia-cyclopentene, IX Alkalische Spaltung des 1.2-Dithia-cyclopentenon-(3)-Rings Leibigs 1965, 683, 132-148
34. Honnalli, S. S.; Ronad, P. M.; Vijaybhasker, K.; Hukkeri, V. I.; Kumar, R. Synthesis and Antimicrobial Activity of Some 2,5-Disubstituted 1,3,4-Oxadiazoles Heterocycl. Commun. 2005, 11, 505-508
35. Siddiqui, A. A.; Arora, A.; Siddiqui, N.; Misra, A. Synthesis of Some 1,2,4-Triazoles as Potential Antifungal Agents Indian J. Chem. B 2005, 44, 838-841
36. De, K.; Legros, J.; Crousse, B.; Bonnet-Delpon, D. Solvent-Promoted and -Controlled Aza-Michael Reaction with Aromatic Amines J. Org. Chem. 2009, 74, 6260-6265
37. Damera, K.; Reddy, K. L.; Sharma, G. V. M. An Efficient ZrCl4 Catalyzed Aza-Michael Addition Reaction: Synthesis of C-Linked Carbo beta(3)-Amino Acids Lett. Org. Chem. 2009, 6) 151-155
38. Kotera, M. Luminescence of Hydrazide Derivatives Containing Rare Earth Elements Nippon Kagaku Kaishi 1979, 1279-1281
39. Bunz, F.; Dutriaux, A.; Lengauer, C.; Waldman, T.; Zhou, S.; Brown, J. P.; Sedivy, J. M.; Kinzler, K. W.; Vogelstein, B. Requirement for p53 and p21 to Sustain G-2 Arrest After DNA Damage Science 1998, 1497-1500